A dose-response relationship of renin-angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study.
Kyung An KimEui-Soon KimJong-Chan YounHye Sun LeeSoyoung JeonHae-Young LeeHyun-Jai ChoJin-Oh ChoiEun-Seok JeonSang Eun LeeMin-Seok KimJae-Joong KimKyung-Kuk HwangMyeong-Chan ChoShung Chull ChaeSeok-Min KangYoungkeun AhnByung-Su YooKye Hun KimByung-Hee OhSang Hong BaekPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
Using RASBs or BBs at discharge was associated with improved survival. A dose-response relationship between RASBs and all-cause mortality was evident in AHFS patients with a reduced ejection fraction but not BBs. It is important to initiate and up-titrate RASBs to the maximally tolerated dose in AHFS patients during the transition period, especially for patients with a reduced ejection fraction.